

# *Fusobacterium nucleatum* in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status



Tsuyoshi Hamada<sup>1</sup>, Xuehong Zhang<sup>2</sup>, Kosuke Mima<sup>3</sup>, Susan Bullman<sup>3,4</sup>, Yasutaka Sukawa<sup>3</sup>, Jonathan A. Nowak<sup>5</sup>, Keisuke Kosumi<sup>1</sup>, Yohei Masugi<sup>1</sup>, Tyler S. Twombly<sup>1</sup>, Yin Cao<sup>6,7,8,9</sup>, Mingyang Song<sup>6,7,8</sup>, Li Liu<sup>1,8,10</sup>, Annacarolina da Silva<sup>1</sup>, Yan Shi<sup>1,11</sup>, Mancang Gu<sup>1,12</sup>, Wanwan Li<sup>1</sup>, Hideo Koh<sup>1</sup>, Katsuhiko Noshō<sup>13</sup>, Kentaro Inamura<sup>14</sup>, NaNa Keum<sup>8,15</sup>, Kana Wu<sup>2,8,16</sup>, Jeffrey A. Meyerhardt<sup>3</sup>, Aleksandar D. Kostic<sup>4,17</sup>, Curtis Huttenhower<sup>4,18</sup>, Wendy S. Garrett<sup>3,4,19</sup>, Matthew Meyerson<sup>3,4</sup>, Edward L. Giovannucci<sup>2,8,16</sup>, Andrew T. Chan<sup>2,6,7</sup>, Charles S. Fuchs<sup>20,21,22</sup>, Reiko Nishihara<sup>1,5,8,16,18</sup>, Marios Giannakis<sup>3,4,23</sup>, and Shuji Ogino<sup>1,4,5,16</sup>

## Abstract

The presence of *Fusobacterium nucleatum* (*F. nucleatum*) in colorectal carcinoma tissue has been associated with microsatellite instability (MSI), lower-level T-cell infiltrates, and poor clinical outcomes. Considering differences in the tumor-immune microenvironment between MSI-high and non-MSI-high carcinomas, we hypothesized that the association of *F. nucleatum* with immune response might differ by tumor MSI status. Using samples from 1,041 rectal and colon cancer patients within the Nurses' Health Study and Health Professionals Follow-up Study, we measured *F. nucleatum* DNA in tumor tissue by a quantitative polymerase chain reaction assay. Multivariable logistic regression models were used to examine the association between *F. nucleatum* status and histopathologic lymphocytic reactions or density of CD3<sup>+</sup> cells, CD8<sup>+</sup> cells, CD45RO (PTPRC)<sup>+</sup> cells, or FOXP3<sup>+</sup> cells in strata of tumor MSI status. We adjusted for potential confounders, including CpG island

methylator phenotype; LINE-1 methylation; and *KRAS*, *BRAF*, and *PIK3CA* mutations. The association of *F. nucleatum* with tumor-infiltrating lymphocytes (TIL) and intratumoral periglandular reaction differed by tumor MSI status ( $P_{\text{interaction}} = 0.002$ ). The presence of *F. nucleatum* was negatively associated with TIL in MSI-high tumors [multivariable odds ratio (OR), 0.45; 95% confidence interval (CI), 0.22–0.92], but positively associated with TIL in non-MSI-high tumors (multivariable OR 1.91; 95% CI, 1.12–3.25). No significant differential association was observed for peritumoral lymphocytic reaction, Crohn-like lymphoid reaction, or T-cell densities. In conclusion, the association of *F. nucleatum* with immune response to colorectal carcinoma differs by tumor MSI status, suggesting that *F. nucleatum* and MSI status interact to affect antitumor immune reactions. *Cancer Immunol Res*; 6(11); 1327–36. ©2018 AACR.

See related Spotlight on p. 1290

<sup>1</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. <sup>2</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. <sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, Massachusetts. <sup>5</sup>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. <sup>6</sup>Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. <sup>7</sup>Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. <sup>8</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. <sup>9</sup>Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. <sup>10</sup>Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Hubei, P.R. China. <sup>11</sup>Department of Medical Oncology, Chinese PLA General Hospital, Beijing, P.R. China. <sup>12</sup>College of Pharmacy, Zhejiang Chinese Medical University, Zhejiang, P.R. China. <sup>13</sup>Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan. <sup>14</sup>Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. <sup>15</sup>Department of Food Science and Biotechnology, Dongguk University, Goyang, the Republic of Korea. <sup>16</sup>Department of Epidemiology, Harvard T.H. Chan School

of Public Health, Boston, Massachusetts. <sup>17</sup>Research Division, Joslin Diabetes Center, Boston, Massachusetts. <sup>18</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. <sup>19</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. <sup>20</sup>Yale Cancer Center, New Haven, Connecticut. <sup>21</sup>Department of Medicine, Yale School of Medicine, New Haven, Connecticut. <sup>22</sup>Smilow Cancer Hospital, New Haven, Connecticut. <sup>23</sup>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

**Note:** Supplementary data for this article are available at Cancer Immunology Research Online (<http://cancerimmunolres.aacrjournals.org/>).

T. Hamada, X. Zhang, K. Mima, and S. Bullman contributed equally as co-first authors. C.S. Fuchs, R. Nishihara, M. Giannakis, and S. Ogino contributed equally as co-last authors.

**Corresponding Authors:** Shuji Ogino, Brigham and Women's Hospital, Boston, MA 02215. Phone: 617-582-9526; Fax: 617-632-8558; E-mail: shuji\_ogino@dfci.harvard.edu; and Marios Giannakis, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Room D1220, Boston, MA 02215. Phone: 617-582-7263; Fax: 617-632-5370; E-mail: marios\_giannakis@dfci.harvard.edu

doi: 10.1158/2326-6066.CIR-18-0174

©2018 American Association for Cancer Research.

## Introduction

Accumulating evidence continues to illustrate the importance of the host immune system in regulating the evolution and progression of neoplastic diseases (1, 2). The colorectum is rich in microbes, and the gut microbiome plays a role in regulating local and systemic immune status (3). *Fusobacterium nucleatum* (*F. nucleatum*) has emerged as a potentially influential bacterium implicated in colorectal carcinogenesis (4–7). Metagenomic and clinical studies have highlighted the enrichment of *F. nucleatum* in colorectal cancer tissue relative to adjacent normal epithelium (5–9), and its persistence in metastatic lesions (10). Experimental evidence indicates that *F. nucleatum* can elicit inflammatory reactions, impair T-cell–mediated antitumor immune response, and promote tumor cell proliferation (11–15). Studies have also demonstrated the association of *F. nucleatum* in colorectal cancer tissue with proximal tumor location, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), lower levels of tumor-infiltrating CD3<sup>+</sup> cells, and poor patient prognosis (8, 16–19).

Colorectal cancer consists of a heterogeneous collection of neoplasms that evolves through stepwise accumulation of genetic and epigenetic aberrations, a process influenced by environmental exposures, the microbiota, and host factors (20–22). MSI-high colorectal carcinomas typically contain numerous frameshift mutations and generate immunogenic peptides ("neoantigens") due to mismatch-repair deficiency, which encourage the antitumor immune response and lead to more favorable prognosis and better response to immunotherapies (23–28). In fact, the FDA approved the use of anti-PDCD1 (programmed cell death 1, PD-1) antibodies pembrolizumab and nivolumab for colorectal cancer with high-level MSI or mismatch-repair deficiency. Considering the differences in the immune microenvironment between MSI-high and non-MSI-high tumors, we hypothesized that the association of *F. nucleatum* in colorectal carcinoma tissue with immune response might differ by tumor MSI status.

To test this hypothesis, we utilized a molecular pathological epidemiology (MPE) database of more than 1,000 colorectal carcinoma cases in two U.S. prospective cohort studies, with data on clinical, pathologic, and tumor molecular characteristics. This comprehensive data set enabled us to assess whether the association of *F. nucleatum* in colorectal cancer tissue with immune response to tumor might differ by MSI status while adjusting for a number of potential confounders.

## Materials and Methods

### Study population

We utilized two prospective cohort studies in the United States, the Nurses' Health Study (NHS, 121,701 women ages 30–55 years followed since 1976) and the Health Professionals Follow-up Study (HPFS, 51,529 men ages 40–75 years followed since 1986). Every two years, participants have been sent follow-up questionnaires to report lifestyle factors and newly diagnosed diseases including colorectal cancer. The follow-up rate was >90% for each follow-up questionnaire in both cohort studies. In both cohorts, the National Death Index was used to ascertain deaths of participants and identify unreported lethal colorectal cancer cases. Study physicians, blinded to exposure data, reviewed medical records of identified colorectal cancer cases to confirm the disease diagnosis

and to collect data on clinical characteristics (e.g., tumor location and disease stage).

Among participants diagnosed with colorectal cancer up to 2012, we analyzed 1,041 cases with available data on *F. nucleatum* and immune response in tumor tissue samples. We included both colon and rectal carcinomas, based on the colorectal continuum model (29, 30). We excluded patients who had been preoperatively treated. We collected formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks from hospitals throughout the United States where colorectal cancer patients had undergone surgical resection. A single pathologist (S. Ogino), blinded to other data, reviewed hematoxylin and eosin–stained tissue sections from all collected blocks and recorded pathologic features. Tumor differentiation was categorized into well/moderate versus poor (>50% vs. ≤50% gland formation, respectively).

Written informed consent was obtained from all participants at enrollment in the NHS and HPFS. This study was conducted in accordance with the Declaration of Helsinki, and after approval by the institutional review boards at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital (Boston, MA).

### Quantitative PCR

DNA was extracted from colorectal cancer tissue in archival FFPE tissue sections using QIAamp DNA FFPE Tissue Kit (Qiagen). As previously described and validated (8), we performed a quantitative PCR assay to measure the amount of *F. nucleatum* DNA in the tumor using custom TaqMan primer/probe sets (Applied Biosystems) for the nusG gene of *F. nucleatum* and the reference human gene *SLCO2A1*. Amplification and detection of DNA were performed using the StepOnePlus Real-Time PCR Systems (Applied Biosystems). Amounts of intratumoral *F. nucleatum* DNA in each specimen were calculated as a relative value normalized to amount of *SLCO2A1* using the  $2^{-\Delta Ct}$  method [where  $\Delta Ct$  (cycle threshold) = "the mean Ct value of *F. nucleatum*" – "the mean Ct value of *SLCO2A1*"] (8). Each specimen was analyzed in duplicate for each target in a single batch, and the mean of the two Ct values was used for each target. In our previous validation study, the Ct values linearly decreased with the amount of input *F. nucleatum* DNA ( $r^2 > 0.99$ ), and the interassay coefficient of variation of the Ct values in five different batches was <1% for all targets (8). Tumors with any detectable *F. nucleatum* DNA were classified as *F. nucleatum*–positive, whereas all other tumors were classified as *F. nucleatum*–negative.

We performed a quantitative PCR assay to measure the amount of *Bifidobacterium* genus DNA in the tumor using custom TaqMan primer/probe sets (Applied Biosystems) for the 16S ribosomal RNA gene of *Bifidobacterium* genus and for the reference gene 16S (31). The primer and probe sequences for each TaqMan Gene-Expression Assay were as follows: *Bifidobacterium* forward primer, 5'-CGGGTGAAGTAATGCGTGACC-3'; *Bifidobacterium* reverse primer, 5'-TGATAGACGCGACCCCA-3'; *Bifidobacterium* FAM probe, 5'-CTCCTGGAACGGGTG-3'; universal 16S forward primer, 5'-CGGTGAATACGTTCCCGG-3'; universal 16S reverse primer, 5'-TACGGCTACCTTGTACGACTT-3'; and universal 16S FAM probe, 5'-CTTGTACACACCGCCCGTC-3'. We used 80 ng DNA in each reaction under the same reaction conditions as for *F. nucleatum* (8). Amounts of intratumoral *Bifidobacterium* genus DNA in each specimen were calculated as a relative value normalized to amounts of 16S using the  $2^{-\Delta Ct}$  method (8). Each specimen was analyzed in duplicate for each target in a single batch, and the mean of the two Ct values was used for each target.

Tumors with any detectable *Bifidobacterium* genus DNA were classified as bifidobacteria-positive, whereas all other tumors were classified as bifidobacteria-negative.

#### MSI status and other molecular characteristics

MSI status was analyzed using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487), as previously described (29). MSI-high was defined as presence of instability in  $\geq 30\%$  of the markers and non-MSI-high as instability in  $< 30\%$  of the markers. Using bisulfite-treated DNA, we determined methylation status of eight CIMP-specific promoters (*CACNA1G*, *CDKN2A*, *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3*, and *SOCS1*) and long interspersed nucleotide element-1 (LINE-1) as previously described (29). CIMP-high was defined as  $\geq 6$  methylated promoters of eight promoters, and CIMP-low/negative as 0–5 methylated promoters. PCR and pyrosequencing were performed for *KRAS* (codons 12, 13, 61, and 146), *BRAF* (codon 600), and *PIK3CA* (exons 9 and 20), as previously described (29). We constructed tissue microarrays of colorectal cancer cases with sufficient tissue materials, including up to four tumor cores from each case in one tissue microarray block (32). As previously described (33, 34), IHC for CD274 (PD-L1) and PDCD1LG2 (PDCD1 ligand 2, PD-L2) was performed using an anti-CD274 (clone MIH1; dilution, 1:50; eBioscience) and anti-PDCD1LG2 (clone 366C.9E5; dilution, 1:6,000; provided by the laboratory of G.J. Freeman), respectively. We assessed overall tumor CD274 expression as an ordinal scale of 0 to 4 by summing cytoplasmic expression score [absent (0), weak (1), moderate (2), or strong (3)] and membrane expression score [absent (0) or present (1)], and categorized CD274 as low (overall score of 0 to 1) or high (2 to 4; ref. 33). We calculated the percentage of tumor cells expressing PDCD1LG2 in the cytoplasm or membrane and grouped the data into bins of 0%–20%, 21%–50%, 51%–80%, or 81%–100% (34).

#### Lymphocytic reaction to colorectal cancer


Lymphocytic reaction to tumor was histopathologically evaluated on whole tissue sections, as previously described (23). Four components of lymphocytic reaction were examined, including tumor-infiltrating lymphocytes (TIL), intratumoral periglandular reaction, peritumoral lymphocytic reaction, and Crohn-like lymphoid reaction (Fig. 1). TIL was defined as lymphocytes on top of cancer cells in a tissue section. Intratumoral periglandular reaction was defined as lymphocytic reaction in tumor stroma within a tumor mass. Peritumoral lymphocytic reaction was defined as discrete lymphoid reaction surrounding a tumor mass. Crohn-like lymphoid reaction was defined as transmural lymphoid reaction. Each of the four components was graded as negative/low, intermediate, or high. A subset of cases ( $n = 398$ ) were independently reviewed by a second pathologist (J.N. Glickman) with a good interobserver correlation as previously described (23). We constructed tissue microarrays and measured densities (cells/mm<sup>2</sup>) of CD3<sup>+</sup> cells, CD8<sup>+</sup> cells, CD45RO (an isoform of the PTPRC protein)<sup>+</sup> cells, and FOXP3<sup>+</sup> cells in colorectal cancer tissue based on IHC and image analysis using an automated scanning microscope and the Ariol image analysis system (Genetix) as previously described (24).

#### Statistical analysis

Our primary hypothesis test assessed a statistical interaction between *F. nucleatum* status in colorectal cancer tissue (positive vs. negative) and MSI status (high vs. non-high) in relation to immune response status. We assessed statistical interactions using the Wald test for the cross-product in multivariable-adjusted logistic regression models. In our primary hypothesis testing on new discoveries, we used the  $\alpha$  level of 0.005. We conducted all other assessments including evaluations of individual odds ratios (ORs) as secondary analyses, and interpreted the results cautiously in addition to use of the  $\alpha$  level of 0.005. Multivariable logistic regression models initially included age (continuous), sex, year of

**Figure 1.**

Lymphocytic reaction to colorectal cancer. **A**, Crohn-like lymphoid reaction (arrows) and peritumoral lymphocytic reaction (asterisks; original magnification, 20 $\times$ ). **B**, Peritumoral lymphocytic reaction (asterisks; original magnification, 40 $\times$ ). **C**, Intratumoral periglandular reaction (asterisks; original magnification, 200 $\times$ ). **D**, Tumor-infiltrating lymphocytes (arrows; original magnification, 400 $\times$ ).



diagnosis (continuous), family history of colorectal cancer (absent vs. present), tumor location (proximal colon vs. distal colon vs. rectum), CIMP status (high vs. low/negative), LINE-1 methylation level (continuous), *KRAS* (mutant vs. wild-type), *BRAF* (mutant vs. wild-type), and *PIK3CA* (mutant vs. wild-type). A backward elimination with a threshold  $P$  of 0.05 was used to select variables for the final models. Cases with missing data [family history of colorectal cancer (0.8%), tumor location (0.3%), CIMP status (5.4%), *KRAS* (7.7%), *BRAF* (1.1%), and *PIK3CA* (6.6%)] were included in the majority category of a given categorical covariate to limit the degrees of freedom of the models. For cases with missing data on LINE-1 methylation level (2.6%), we assigned a separate indicator variable. We confirmed that the exclusion of cases with missing data in any of the variables did not substantially alter our results. The proportional odds assumption was assessed using the ordinal logistic regression model. We observed evidence of violation of this assumption in three of the four lymphocytic reaction patterns (TIL, intratumoral periglandular reaction, and peritumoral lymphocytic reaction) and T-cell quartile variables. We therefore used binary histologic lymphocytic reaction variables and T-cell variables dichotomized at the median value as outcome variables in logistic regression analyses.

In secondary analyses, we assessed a statistical interaction between *F. nucleatum* status in colorectal cancer tissue (positive vs. negative) and MSI status (high vs. non-high) in relation to colorectal cancer-specific or overall mortality. We assessed statistical interactions using the Wald test for the cross-product in multivariable-adjusted Cox proportional hazards regression models. Multivariable Cox regression models initially included tumor differentiation (well-moderate vs. poor) and disease stage (I/II vs. III/IV) in addition to the same set of covariates as in the multivariable logistic regression models. A backward elimination with a threshold  $P$  of 0.05 was used to select variables for the final models. Cases with missing data on tumor differentiation (0.1%) were included in the majority category, and the other covariates were dealt as in the multivariable logistic regression models. We confirmed that the exclusion of cases with missing data in any of the variables did not substantially alter our results. The assumption of proportionality of hazards was generally satisfied using the assessment of a time-varying covariate, that is, the cross-product of *F. nucleatum* status and survival time in strata of MSI status ( $P > 0.2$ ). Cumulative survival probabilities were estimated using the Kaplan–Meier method and compared using the log-rank test. For colorectal cancer-specific mortality, deaths from other causes were treated as censored events. Using a single regression model with reparameterization of an interaction term (32), we calculated ORs for immune response status and hazard ratios for colorectal cancer mortality comparing *F. nucleatum*-positive to *F. nucleatum*-negative tumors in the two strata of MSI status.

All statistical analyses were performed using SAS software (version 9.4; SAS Institute), and all  $P$  values were two-sided.

## Results

Among the 1,041 colorectal carcinoma cases from the two prospective cohort studies, *F. nucleatum* DNA was detected using the quantitative PCR assay in 135 (13%) cases. Table 1 shows clinical, pathologic, and molecular features of colorectal cancer cases according to combined tumor tissue *F. nucleatum* and MSI status. As previously reported (8), MSI-high tumors were associated with detectable *F. nucleatum* DNA. There was a trend toward a

higher rate of detectable intratumor *F. nucleatum* in more recent cases, particularly for MSI-high tumors. High persistence of *F. nucleatum* has been observed in metastatic liver lesions from *F. nucleatum*-positive colorectal cancer (10). We examined the correlations between *F. nucleatum* and disease stage in strata of tumor MSI status. We observed a significant positive correlation between *F. nucleatum* and disease stage in non-MSI-high tumors ( $P = 0.004$ , with the  $\alpha$  level of 0.005), but not in MSI-high tumors ( $P = 0.34$ ). However, statistical power was limited in the analysis of MSI-high tumors.

Table 2 shows the distribution of colorectal carcinoma cases according to *F. nucleatum* status and histologic lymphocytic reaction patterns in strata of MSI status. The presence of *F. nucleatum* in tumor tissue was negatively correlated with intratumoral periglandular reaction in MSI-high tumors ( $P = 0.002$ , with the  $\alpha$  level of 0.005) and was positively correlated with Crohn-like lymphoid reaction in non-MSI-high tumors ( $P = 0.001$ ).

In our primary hypothesis test using logistic regression models (Table 3; Supplementary Table S1), we observed a statistically significant interaction between *F. nucleatum* and MSI status in relation to TIL or intratumoral periglandular reaction ( $P_{\text{interaction}} = 0.002$ , with the  $\alpha$  level of 0.005). The presence of *F. nucleatum* in tumor tissue was negatively associated with degrees of TIL in MSI-high colorectal cancer [multivariable OR, 0.45; 95% confidence interval (CI), 0.22–0.92], but positively associated with TIL in non-MSI-high cancer (multivariable OR, 1.91; 95% CI, 1.12–3.25). Similarly, the presence of *F. nucleatum* in tumor tissue was negatively associated with intratumoral periglandular reaction in MSI-high tumors (multivariable OR, 0.43; 95% CI, 0.21–0.87), but positively associated with intratumoral periglandular reaction (multivariable OR, 1.97, 95% CI, 1.00–3.86) in non-MSI-high tumors. The statistical interaction of *F. nucleatum* and MSI status in relation to peritumoral lymphocytic reaction or Crohn-like lymphoid reaction was not significant with the  $\alpha$  level of 0.005 ( $P_{\text{interaction}} > 0.01$ ).

As secondary analyses using a subset of cases with available tissue microarray data (up to 580 cases), we examined the association of *F. nucleatum* with densities of T-cell subsets ( $CD3^+$  cells,  $CD8^+$  cells,  $CD45RO^+$  cells, or  $FOXP3^+$  cells) in strata of MSI status. Although we did not observe a significant interaction between *F. nucleatum* and MSI status in relation to the density of  $CD3^+$  cells,  $CD8^+$  cells,  $CD45RO^+$  cells, or  $FOXP3^+$  cells ( $P_{\text{interaction}} > 0.1$ , with the  $\alpha$  level of 0.005; Supplementary Table S2), statistical power was limited in these analyses.

We did not observe a statistically significant interaction between *Bifidobacterium* genus and MSI status in relation to lymphocytic reaction patterns or densities of T-cell subsets ( $P_{\text{interaction}} > 0.1$ , with the  $\alpha$  level of 0.005).

As secondary analyses to assess the prognostic association of *F. nucleatum* in strata of MSI status, we conducted Kaplan–Meier analyses and Cox regression analyses, and did not observe a significant interaction between *F. nucleatum* and MSI status in relation to colorectal cancer-specific or overall mortality (Supplementary Fig. S1; Supplementary Table S3).

## Discussion

Using two large prospective cohort studies in the United States, we tested the hypothesis that the association of intratumoral *F. nucleatum* status with local immune response to colorectal cancer might differ by tumor MSI status. We found negative

**Table 1.** Clinical, pathologic, and molecular characteristics of patients with colorectal cancer and their samples, according to *F. nucleatum* status in tumor tissue, stratified by MSI status

Characteristic	All cases <sup>a</sup> (n = 1,041)	Non-MSI-high		MSI-high	
		<i>F. nucleatum</i> in tumor		<i>F. nucleatum</i> in tumor	
		Negative <sup>a</sup> (n = 787)	Positive <sup>a</sup> (n = 77)	Negative <sup>a</sup> (n = 119)	Positive <sup>a</sup> (n = 58)
<b>Sex</b>					
Female (NHS)	609 (59%)	437 (56%)	42 (55%)	85 (71%)	45 (78%)
Male (HPFS)	432 (41%)	350 (44%)	35 (45%)	34 (29%)	13 (22%)
Mean age ± SD (years)	69.5 ± 8.9	68.9 ± 9.0	69.5 ± 9.6	72.1 ± 7.6	72.5 ± 8.4
<b>Race/ethnicity</b>					
White	995 (97%)	751 (97%)	74 (99%)	114 (97%)	56 (98%)
Black	16 (1.6%)	13 (1.7%)	0	2 (1.7%)	1 (1.8%)
Other	11 (1.1%)	8 (1.0%)	1 (1.3%)	2 (1.7%)	0
<b>Year of diagnosis</b>					
1995 or before	343 (33%)	285 (36%)	21 (27%)	29 (24%)	8 (14%)
1996–2000	286 (27%)	216 (27%)	25 (32%)	33 (28%)	12 (21%)
2001–2012	412 (40%)	286 (36%)	31 (40%)	57 (48%)	38 (66%)
<b>Family history of colorectal cancer</b>					
In first-degree relative(s)					
Absent	829 (80%)	632 (81%)	66 (88%)	84 (71%)	47 (81%)
Present	204 (20%)	150 (19%)	9 (12%)	34 (29%)	11 (19%)
<b>Prediagnosis body mass index<sup>b</sup></b>					
<25 kg/m <sup>2</sup>	417 (40%)	311 (40%)	30 (39%)	49 (42%)	27 (47%)
25–29.9 kg/m <sup>2</sup>	424 (41%)	330 (42%)	35 (46%)	43 (36%)	16 (28%)
≥30 kg/m <sup>2</sup>	194 (19%)	142 (18%)	11 (14%)	26 (22%)	15 (26%)
<b>Prudent dietary pattern<sup>c</sup></b>					
Quartile 1 (lowest)	258 (25%)	187 (24%)	25 (33%)	30 (25%)	16 (28%)
Quartile 2	258 (25%)	206 (26%)	19 (25%)	21 (18%)	12 (21%)
Quartile 3	257 (25%)	187 (24%)	21 (28%)	32 (27%)	17 (29%)
Quartile 4 (highest)	258 (25%)	199 (26%)	11 (14%)	35 (30%)	13 (22%)
<b>Western dietary pattern<sup>c</sup></b>					
Quartile 1 (lowest)	258 (25%)	198 (25%)	10 (13%)	31 (26%)	19 (33%)
Quartile 2	258 (25%)	192 (25%)	21 (28%)	32 (27%)	13 (22%)
Quartile 3	258 (25%)	200 (26%)	20 (26%)	21 (18%)	17 (29%)
Quartile 4 (highest)	258 (25%)	190 (24%)	25 (33%)	34 (29%)	9 (16%)
<b>Tumor location</b>					
Proximal colon	522 (50%)	332 (42%)	33 (43%)	104 (87%)	53 (91%)
Distal colon	297 (29%)	264 (34%)	20 (26%)	10 (8.4%)	3 (5.2%)
Rectum	219 (21%)	189 (24%)	23 (30%)	5 (4.2%)	2 (3.5%)
<b>Tumor differentiation</b>					
Well to moderate	936 (90%)	745 (95%)	67 (88%)	86 (72%)	38 (66%)
Poor	104 (10%)	42 (5.3%)	9 (12%)	33 (28%)	20 (34%)
<b>AJCC disease stage</b>					
I	239 (25%)	197 (27%)	8 (11%)	25 (22%)	9 (17%)
II	314 (33%)	199 (28%)	21 (30%)	64 (56%)	30 (56%)
III	280 (29%)	222 (31%)	28 (39%)	18 (16%)	12 (22%)
IV	127 (13%)	103 (14%)	14 (20%)	7 (6.1%)	3 (5.6%)
<b>CIMP status</b>					
CIMP-low/negative	794 (81%)	688 (92%)	68 (94%)	24 (21%)	14 (25%)
CIMP-high	191 (19%)	56 (7.5%)	4 (5.6%)	89 (79%)	42 (75%)
Mean LINE-1 methylation level ± SD (%)	63.6 ± 10.4	62.6 ± 10.2	62.2 ± 9.4	68.4 ± 10.3	70.5 ± 9.5
<b>KRAS mutation</b>					
Wild-type	541 (56%)	390 (52%)	30 (41%)	88 (85%)	33 (82%)
Mutant	420 (44%)	353 (48%)	44 (59%)	16 (15%)	7 (18%)
<b>BRAF mutation</b>					
Wild-type	858 (83%)	709 (91%)	73 (95%)	55 (47%)	21 (37%)
Mutant	172 (17%)	70 (9.0%)	4 (5.2%)	62 (53%)	36 (63%)
<b>PIK3CA mutation</b>					
Wild-type	812 (84%)	617 (84%)	59 (81%)	91 (84%)	45 (85%)
Mutant	160 (16%)	121 (16%)	14 (19%)	17 (16%)	8 (15%)
<b>Tumor CD274 (PD-L1) expression</b>					
Low	263 (41%)	176 (37%)	29 (52%)	37 (46%)	21 (64%)
High	377 (59%)	294 (63%)	27 (48%)	44 (54%)	12 (36%)
<b>Tumor PDCD1LG2 (PD-L2) expression</b>					
0%–20%	160 (25%)	111 (24%)	19 (37%)	22 (28%)	8 (25%)
21%–50%	148 (23%)	110 (23%)	11 (21%)	17 (21%)	10 (31%)
51%–80%	197 (31%)	150 (32%)	12 (23%)	25 (31%)	10 (31%)
81%–100%	129 (20%)	99 (21%)	10 (19%)	16 (20%)	4 (13%)
<b>Bifidobacterium genus DNA</b>					
Negative	748 (73%)	576 (75%)	54 (71%)	82 (69%)	36 (63%)
Positive	276 (27%)	197 (25%)	22 (29%)	36 (31%)	21 (37%)

Abbreviations: AJCC, American Joint Committee on Cancer; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; SD, standard deviation.

<sup>a</sup>Percentage indicates the proportion of cases with a specific clinical, pathologic, or molecular characteristic in all cases or in strata of *F. nucleatum* and MSI status. Total percentages may not equal 100% due to rounding.

<sup>b</sup>Calculated by dividing weight (kilogram) by squared height (meter).

<sup>c</sup>The prudent dietary pattern is characterized by high intake of vegetables, fruits, fish, poultry, and whole grains, and the Western dietary pattern is characterized by high intake of red and processed meats, added sugar, and refined grains (42).

Downloaded from <http://aacrjournals.org/cancerimmunolres/article-pdf/6/11/1327/2352095/1327.pdf> by guest on 14 February 2025

**Table 2.** Distribution of colorectal cancer samples according to *F. nucleatum* status in tumor tissue and lymphocytic reaction status, stratified by MSI status

		All cases <sup>a</sup>	<i>F. nucleatum</i> in colorectal cancer tissue		<i>P</i> <sup>b</sup>		
			Negative <sup>a</sup>	Positive <sup>a</sup>			
Non-MSI-high	TILs (n = 862)				0.013		
	Negative/low	699 (81%)	644 (82%)	55 (71%)			
	Intermediate	119 (14%)	107 (14%)	12 (16%)			
		High	44 (5.1%)	34 (4.3%)	10 (13%)	0.57	
	Intratumoral periglandular reaction (n = 863)						
	Negative/low	124 (14%)	106 (13%)	18 (23%)			
		Intermediate	660 (76%)	613 (78%)	47 (61%)	0.89	
		High	79 (9.2%)	67 (8.5%)	12 (16%)		
	Peritumoral lymphocytic reaction (n = 859)						
		Negative/low	138 (16%)	123 (16%)	15 (20%)	0.001	
		Intermediate	615 (72%)	567 (72%)	48 (63%)		
		High	106 (12%)	93 (12%)	13 (17%)		
	Crohn-like lymphoid reaction (n = 723)				0.055		
	Negative/low	586 (81%)	544 (83%)	42 (66%)			
	Intermediate	111 (15%)	92 (14%)	19 (30%)			
	High	26 (3.6%)	23 (3.5%)	3 (4.7%)	0.002		
MSI-high	TILs (n = 177)						
	Negative/low	46 (26%)	25 (21%)	21 (36%)		0.062	
		Intermediate	64 (36%)	45 (38%)	19 (33%)		
		High	67 (38%)	49 (41%)	18 (31%)		
		Intratumoral periglandular reaction (n = 177)				0.13	
		Negative/low	12 (6.8%)	1 (0.8%)	11 (19%)		
		Intermediate	100 (56%)	68 (57%)	32 (55%)		
		High	65 (37%)	50 (42%)	15 (26%)	0.062	
		Peritumoral lymphocytic reaction (n = 177)					
		Negative/low	13 (7.3%)	4 (3.4%)	9 (16%)		
			Intermediate	91 (51%)	62 (52%)	29 (50%)	0.13
			High	73 (41%)	53 (45%)	20 (34%)	
	Crohn-like lymphoid reaction (n = 151)						
	Negative/low	64 (42%)	41 (41%)	23 (44%)	0.13		
		Intermediate	48 (32%)	26 (26%)		22 (42%)	
		High	39 (26%)	32 (32%)		7 (13%)	

<sup>a</sup>Percentage indicates the proportion of cases with a specific level of lymphocytic reaction in strata of MSI status or in strata of *F. nucleatum* and MSI status. Total percentages may not equal 100% due to rounding.

<sup>b</sup>*P* value was calculated using the Spearman correlation test between *F. nucleatum* status (positive vs. negative) and each lymphocytic reaction variable [ordinal; negative/low (0), intermediate (1), and high (2)].

associations of *F. nucleatum* status with degrees of TIL and intratumoral periglandular reaction in MSI-high colorectal carcinomas and positive associations with those reaction patterns in non-MSI-high carcinomas. Our findings suggest an interplay between *F. nucleatum*, MSI status, and immune cells in colorectal tumor.

High-level infiltration of lymphocytes in colorectal cancer has been associated with better clinical outcomes (23, 24, 35, 36), and therapeutic activation of antitumor immune response in the tumor microenvironment has become an attractive strategy for cancer immunotherapy (37–39). In particular, immune-checkpoint inhibitors that target the PDCD1 (PD-1) or CD274 (PDCD1 ligand 1, PD-L1) protein have shown promise in treating various cancer types (37–39), including colorectal cancer with high MSI (26–28). However, despite the accompanying intense immune response, some MSI-high colorectal cancers can evade the immune eradication, and not all MSI-high tumors respond to the immune-checkpoint blockade. Therefore, immunosuppressive factors in MSI-high colorectal cancer need to be elucidated to improve the efficacy of immunotherapies in colorectal cancer. In the tumor microenvironment, host cells, neoplastic cells, and microbiota form complex interactive networks. A better understanding of these interactions would have relevance to existing avenues of treatment and may also reveal additional strategies for combating cancer (40, 41).

Alterations in the gut microbial composition are considered to play a role in colorectal cancer development (3, 42, 43). Fiber-rich diets are associated with a lower risk of colorectal cancer containing abundant *F. nucleatum* (42). Our findings of a possible temporal increase in detectable intratumor *F. nucleatum* might be due to growing popularity of colonoscopy screening, changes in dietary and lifestyle patterns, and/or aging of the cohort participants. Such interactions might become evident with a longitudinal epidemiologic investigation. Mechanistic studies indicate that *F. nucleatum* can exert carcinogenic effects through binding of its adhesin FadA to CDH1 (E-cadherin) and resultant activation of the CTNNB1 (beta-catenin)/WNT signaling pathway in colorectal carcinoma cells (44) as well as through suppression of the adaptive immune response (12). WNT signaling activation has been linked to immunosuppression in colorectal carcinoma (45). Experimental evidence suggests that binding of the virulence factor FAP2 to a host factor Gal-GalNAc may lead to interaction with the inhibitory immune cell receptor TIGIT, thereby inhibiting T-cell activity and NK cell cytotoxicity (11, 13, 46). In line with these studies, our previous population-based study has shown inverse associations of the enrichment of *F. nucleatum* in colorectal cancer tissue with CD3<sup>+</sup> pan-T-cell density and patient survival (8, 18). *F. nucleatum* also increases numbers of myeloid-derived suppressor cells and tumor-associated macrophages in the colorectal tumor microenvironment (12, 47), contributing to

**Table 3.** Logistic regression analyses to assess the association of *F. nucleatum* status in colorectal cancer tissue with lymphocytic reaction status, in strata of MSI status

		Univariable OR (95% CI)	Multivariable OR (95% CI) <sup>a</sup>
Model for TILs <sup>b</sup> (as an outcome variable; n = 1,039)			
Non-MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	1.83 (1.08–3.09)	1.91 (1.12–3.25)
MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	0.47 (0.23–0.94)	0.45 (0.22–0.92)
<i>P</i> <sub>interaction</sub> <sup>c</sup>		0.002	0.002
Model for intratumoral periglandular reaction <sup>b</sup> (as an outcome variable; n = 1,040)			
Non-MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	1.98 (1.02–3.85)	1.97 (1.00–3.86)
MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	0.48 (0.24–0.96)	0.43 (0.21–0.87)
<i>P</i> <sub>interaction</sub> <sup>c</sup>		0.004	0.002
Model for peritumoral lymphocytic reaction <sup>b</sup> (as an outcome variable; n = 1,036)			
Non-MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	1.53 (0.81–2.89)	1.44 (0.76–2.76)
MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	0.66 (0.34–1.26)	0.54 (0.27–1.05)
<i>P</i> <sub>interaction</sub> <sup>c</sup>		0.068	0.038
Model for Crohn-like lymphoid reaction <sup>b</sup> (as an outcome variable; n = 874)			
Non-MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	2.48 (1.42–4.31)	2.86 (1.62–5.06)
MSI-high	<i>F. nucleatum</i> -negative	1 (referent)	1 (referent)
	<i>F. nucleatum</i> -positive	0.89 (0.45–1.76)	0.99 (0.49–1.98)
<i>P</i> <sub>interaction</sub> <sup>c</sup>		0.022	0.020


<sup>a</sup>The multivariable logistic regression model initially included sex, age at diagnosis, year of diagnosis, family history of colorectal cancer, tumor location, CpG island methylator phenotype-specific promoter status, long interspersed nucleotide element-1 methylation level, and *KRAS*, *BRAF*, and *PIK3CA* mutations. A backward elimination with a threshold *P* of 0.05 was used to select variables for the final models. The variables that remained in the final models for TILs and intratumoral periglandular reaction were shown in Supplementary Table S1.

<sup>b</sup>To avoid violation of the proportional odds assumption, the most common score or less (i.e., 0 for TILs and Crohn-like lymphoid reaction; and 0–1 for intratumoral periglandular reaction and peritumoral lymphocytic reaction) was categorized as low, and higher score was categorized as high.

<sup>c</sup>*P*<sub>interaction</sub> (two-sided) was calculated using the Wald test for the cross-product of *F. nucleatum* status (positive vs. negative) and MSI status (high vs. non-high) in the logistic regression model.

proinflammatory reactions and impairment of tumor-specific immune responses.

Previous studies have linked *F. nucleatum* to MSI-high colorectal cancer (8, 16, 17), which is characterized by a vigorous antitumor immune response in the tumor microenvironment resulting from frameshift mutations and high expression of immunogenic peptides (23–27). However, there is a paradoxical



**Figure 2.** *F. nucleatum* and lymphocytic reaction to colorectal carcinoma according to tumor MSI status. The current study suggests that *F. nucleatum* may attenuate adaptive immune response to MSI-high colorectal carcinomas, which exhibit abundant immunogenic neoantigens. In contrast, the proinflammatory properties of *F. nucleatum* may lead to lymphocytic reaction to non-MSI-high carcinomas that contain lower amounts of neoantigens and tumor-infiltrating lymphocytes than MSI-high carcinomas.

finding that the presence of detectable *F. nucleatum* in tumor tissue is inversely associated with CD3<sup>+</sup> T-cell density (8). Our current findings suggest that *F. nucleatum* may exert suppressive effects on adaptive antitumor immune response in MSI-high colorectal cancer with abundant immunogenic neoantigens (Fig. 2). During the development of colorectal carcinomas, MSI-high tumors need to acquire the means to resist antitumor immune activity. Our study provides evidence suggesting that infection with *F. nucleatum* may promote immune evasion in the immune cell-rich microenvironment of MSI-high colorectal carcinomas. We did not observe differential associations of *F. nucleatum* with T-cell subsets (CD3<sup>+</sup> cells, CD8<sup>+</sup> cells, CD45RO<sup>+</sup> cells, and FOXP3<sup>+</sup> cells) by tumor MSI status. These seemingly conflicting findings might be due to the roles of other cell types in immune reactions to tumor, measurement errors in T-cell densities, and/or a smaller overall sample size in analyses of T cells.

The trend toward more lymphocytic reaction associated with *F. nucleatum* in non-MSI-high tumors warrants further discussion. In addition to suppression of the antitumor immune response, *F. nucleatum* can exert proinflammatory effects in the colorectal mucosa (12, 14, 15) and has been implicated in pathogenesis of inflammatory bowel diseases (14). Studies have shown that *F. nucleatum* may increase expression of proinflammatory cytokines and upregulate the NF-κB pathway (12, 48) in colorectal tumors. Therefore, we speculate that the proinflammatory effects of *F. nucleatum* may outweigh its immunosuppressive effects in non-MSI-high tumors, which contain fewer neoantigens and

Downloaded from http://aacrjournals.org/cancerimmunolres/article-pdf/6/11/1327/2352096/1327.pdf by guest on 14 February 2025

fewer tumor-infiltrating immune cells on average relative to MSI-high tumors (Fig. 2). These divergent associations of tumor tissue *F. nucleatum* with lymphocytic reactions between MSI-high and non-MSI-high tumors underscore the importance of interactive effects of environmental and tumor molecular features on host immune response in the tumor microenvironment (40).

We acknowledge limitations of our study. Our study focused on limited numbers of microbial species and immune reaction components. Accumulating evidence points to the roles of a variety of microbes and immune cells in antitumor immune responses and carcinogenesis (2, 3, 49). Therefore, more comprehensive analyses are warranted to investigate the interactions between microbes other than *F. nucleatum* (e.g., enterotoxigenic *Bacteroides fragilis* and pks-positive *Escherichia coli*; ref. 4) and other immune parameters (e.g., myeloid-derived suppressor cells, tumor-associated macrophages, and TIGIT-expressing cells). High-throughput sequencing-based analyses including 16S rRNA gene sequencing, metagenomic analyses, gene-expression profiling, and T-cell receptor sequencing would also provide insights into the interrelationship of tumor molecular markers and microbiota in relation to antitumor immune response. Detailed data on antibiotics and cancer treatments including immune-checkpoint inhibitors were not available in our study. There might be confounding factors that were unaccounted for; nonetheless, we adjusted for a variety of demographic, clinical, and tumor characteristics, as we utilized the MPE database. Another limitation is the cross-sectional study design, which dictates that we cannot rule out reverse causation. It is possible that immune responses may alter the amount of *F. nucleatum* in the tumor microenvironment. However, our hypothesis was based on accumulating evidence for the suppressive effects of *F. nucleatum* on T-cell-mediated antitumor immunity (8, 11–13). We used the quantitative PCR assay for *F. nucleatum* in FFPE tissue specimens; therefore, tissue processing procedures and storage conditions might have affected the detection rate. Nonetheless, our previous validation study using quantitative PCR showed concordance in detecting *F. nucleatum* in paired FFPE and frozen tissue specimens and linearity and reproducibility of *F. nucleatum* measurements in FFPE tissue specimens (8). Finally, our findings need to be validated in independent cohorts.

The current study has strengths, including the use of the MPE (40, 41) database derived from two U.S. prospective cohort studies, and this study represents the integration of immunology into the MPE paradigm (i.e., immunology-MPE; ref. 50). The data on the amount of *F. nucleatum* DNA in the tumor, tumor molecular characteristics, and pathologic findings in over 1,000 cases allowed us to comprehensively examine possible differential roles of *F. nucleatum* in MSI-high and non-MSI-high colorectal cancers. Our study population was derived from a large number of incident colorectal cancer cases that occurred in the well-defined populations of the prospective cohorts, and cases were also derived from hospitals in 48 states in the United States; both features increase the generalizability of our findings. Nevertheless, our findings need to be validated in independent studies.

In conclusion, the current study provides evidence for divergent effects of *F. nucleatum* in the tumor microenvironment according to tumor MSI status. There may be dominant suppressive effects of *F. nucleatum* on adaptive antitumor immune responses in MSI-high colorectal cancer and apparent proinflammatory effects in non-MSI-high cancer. Our findings, if validated, would inform

future mechanistic studies examining the interplay of *F. nucleatum* and tumor characteristics in colorectal tumor evolution.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

### Authors' Contributions

**Conception and design:** T. Hamada, X. Zhang, K. Mima, K. Kosumi, M. Song, L. Liu, A.D. Kostic, W.S. Garrett, M. Meyerson, E.L. Giovannucci, M. Giannakis, S. Ogino

**Development of methodology:** T. Hamada, K. Mima, S. Bullman, Y. Sukawa, K. Kosumi, L. Liu, C. Huttenhower, W.S. Garrett, A.T. Chan, S. Ogino

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** T. Hamada, K. Mima, Y. Sukawa, K. Kosumi, Y. Masugi, Y. Shi, M. Gu, W. Li, H. Koh, K. Inamura, E.L. Giovannucci, A.T. Chan, C.S. Fuchs, M. Giannakis, S. Ogino

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** X. Zhang, K. Mima, S. Bullman, J.A. Nowak, K. Kosumi, Y. Cao, M. Song, L. Liu, Y. Shi, H. Koh, K. Nosh, N. Keum, K. Wu, J.A. Meyerhardt, C.S. Fuchs, R. Nishihara, M. Giannakis, S. Ogino

**Writing, review, and/or revision of the manuscript:** T. Hamada, X. Zhang, S. Bullman, J.A. Nowak, K. Kosumi, Y. Masugi, T.S. Twombly, Y. Cao, M. Song, L. Liu, A. da Silva, Y. Shi, M. Gu, H. Koh, N. Keum, K. Wu, J.A. Meyerhardt, W.S. Garrett, M. Meyerson, E.L. Giovannucci, A.T. Chan, M. Giannakis, S. Ogino

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** Y. Sukawa, Y. Masugi, L. Liu, A. da Silva, A.T. Chan, S. Ogino

**Study supervision:** J.A. Nowak, A.T. Chan, C.S. Fuchs, M. Giannakis, S. Ogino

### Acknowledgments

This work was supported by NIH grants (P01 CA87969 to M.J. Stampfer; UM1 CA186107 to M.J. Stampfer; P01 CA55075 to W.C. Willett; UM1 CA167552 to W.C. Willett; U01 CA167552 to W.C. Willett and L.A. Mucci; P50 CA127003 to C.S. Fuchs; R01 CA118553 to C.S. Fuchs; R01 CA169141 to C.S. Fuchs; R01 CA137178 to A.T. Chan; K24 DK098311 to A.T. Chan; R35 CA197735 to S. Ogino; R01 CA151993 to S. Ogino; K07 CA190673 to R. Nishihara; and K07 CA188126 to X. Zhang); by Nodal Award (2016-02) from the Dana-Farber Harvard Cancer Center (to S. Ogino); and by grants from the Project P Fund, The Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. Research supported by a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (grant number: SU2C-AACR-DT22-17) was awarded to C.S. Fuchs and M. Giannakis. Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. T. Hamada was supported by a fellowship grant from the Mitsukoshi Health and Welfare Foundation. K. Mima was supported by a grant from Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers from Japan Society for the Promotion of Science. K. Kosumi was supported by grants from Overseas Research Fellowship (JP2017-775) and Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers, from Japan Society for the Promotion of Science. M. Song was supported by the 2017 AACR-AstraZeneca Fellowship in Immuno-oncology Research (grant number 17-40-12-SONG). L. Liu was supported by a scholarship grant from Chinese Scholarship Council and a fellowship grant from Huazhong University of Science and Technology. N. Keum was supported by grants from the National Research Foundation of Korea (NRF-2018R1C1B6008822; NRF-2018R1A4A1022589). M. Giannakis was supported by a KL2/Catalyst Medical Research Investigator Training award (NIH award, KL2 TR001100).

We would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-up Study for their valuable contributions



as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The authors assume full responsibility for analyses and interpretation of these data.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 19, 2018; revised July 3, 2018; accepted September 11, 2018; published first September 18, 2018.

## References

- Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. *Nat Immunol* 2017;18:843–50.
- Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. *Nat Rev Clin Oncol* 2017;14:717–34.
- Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: evidence of association and causality. *Semin Immunol* 2017;32:25–34.
- Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. *Cancer Cell* 2018;33:954–64.
- Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res* 2012;22:292–8.
- Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res* 2012;22:299–306.
- Li YY, Ge QX, Cao J, Zhou YJ, Du YL, Shen B, et al. Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients. *World J Gastroenterol* 2016;22:3227–33.
- Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. *Fusobacterium nucleatum* and T cells in colorectal carcinoma. *JAMA Oncol* 2015;1:653–61.
- Repass J, Iorns E, Denis A, Williams SR, Perfito N, Errington TM. Replication study: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Elife* 2018;7:e25801.
- Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science* 2017;358:1443–8.
- Kaplan CW, Ma X, Paranjpe A, Jewett A, Lux R, Kinder-Haake S, et al. *Fusobacterium nucleatum* outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. *Infect Immun* 2010;78:4773–8.
- Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 2013;14:207–15.
- Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* 2015;42:344–55.
- Bashir A, Miskeen AY, Hazari YM, Asrafuzzaman S, Fazili KM. *Fusobacterium nucleatum*, inflammation, and immunity: the fire within human gut. *Tumour Biol* 2016;37:2805–10.
- Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, et al. *Fusobacterium nucleatum* subspecies *animalis* influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. *Cancer Prev Res (Phila)* 2017;10:398–409.
- Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. *Fusobacterium nucleatum* associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis* 2014;33:1381–90.
- Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, et al. Association of *Fusobacterium nucleatum* with immunity and molecular alterations in colorectal cancer. *World J Gastroenterol* 2016;22:557–66.
- Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut* 2016;65:1973–80.
- Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. *Fusobacterium nucleatum* promotes chemoresistance to colorectal cancer by modulating autophagy. *Cell* 2017;170:548–63e16.
- Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011;60:397–411.
- Rajpoot M, Sharma AK, Sharma A, Gupta GK. Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. *Semin Cancer Biol* 2018in press.
- Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, et al. Carcinogenesis as a result of multiple inflammatory and oxidative hits: a comprehensive review from tumor microenvironment to gut microbiota. *Neoplasia* 2018;20:721–33.
- Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res* 2009;15:6412–20.
- Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. *J Pathol* 2010;222:350–66.
- Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. *Cell Rep* 2016;15:857–65.
- Li SK, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. *Trends Mol Med* 2016;22:274–89.
- Llona NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov* 2015;5:43–51.
- Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409–13.
- Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut* 2012;61:847–54.
- Mima K, Cao Y, Chan AT, Qian ZR, Nowak JA, Masugi Y, et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue according to tumor location. *Clin Transl Gastroenterol* 2016;7:e200.
- Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* 2015;350:1084–9.
- Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. *PLoS One* 2008;3:e3698.
- Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (Programmed Cell Death 1 Ligand 1) expression status. *J Clin Oncol* 2017;35:1836–44.
- Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. *Cancer Immunol Res* 2017;5:1046–55.
- Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* 2018;391:2128–39.
- Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, et al. Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer. *J Natl Cancer Inst* 2016;108:djw027.
- Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, et al. Immunotherapy for colorectal cancer: where are we heading? *Expert Opin Biol Ther* 2017;17:709–21.

38. Grizzi F, Basso G, Borroni EM, Cavalleri T, Bianchi P, Stifter S, et al. Evolving notions on immune response in colorectal cancer and their implications for biomarker development. *Inflamm Res* 2018;67:375–89.
39. Gang W, Wang JJ, Guan R, Yan S, Shi F, Zhang JY, et al. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. *Cancer Med* 2018;7:1578–603.
40. Ogino S, Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA Jr, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. *Gut* 2018;67:1168–80.
41. Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. *J Gastroenterol* 2017;52:265–75.
42. Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by *Fusobacterium nucleatum* in tumor tissue. *JAMA Oncol* 2017;3:921–7.
43. Park CH, Han DS, Oh YH, Lee AR, Lee YR, Eun CS. Role of *Fusobacteria* in the serrated pathway of colorectal carcinogenesis. *Sci Rep* 2016;6: 25271.
44. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ beta-catenin signaling via its FadA adhesin. *Cell Host Microbe* 2013;14: 195–206.
45. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, et al. Genetic mechanisms of immune evasion in colorectal cancer. *Cancer Discov* 2018;8:730–49.
46. Abed J, Emgard JE, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 mediates *Fusobacterium nucleatum* colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. *Cell Host Microbe* 2016;20:215–25.
47. Park HE, Kim JH, Cho NY, Lee HS, Kang GH. Intratumoral *Fusobacterium nucleatum* abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. *Virchows Arch* 2017;471:329–36.
48. Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. *Fusobacterium nucleatum* increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of MicroRNA-21. *Gastroenterology* 2017;152:851–66e24.
49. Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. *Cancer Discov* 2018;8:403–16.
50. Ogino S, Giannakis M. Immunoscore for (colorectal) cancer precision medicine. *Lancet* 2018;391:2084–6.